Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05874193 | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma(COSTA) | withdrawn | Phase 2 | 0 | Cristiana Costa Chase, DOOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | withdrawn | Phase 1 / Phase 2 | 0 | Kevin McNerneyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)(LINKER-MM8) | withdrawn | Phase 2 / Phase 3 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05312476 | Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides(Resimmune®) | withdrawn | Phase 2 | 0 | Virogen Biotechnology Inc.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT05846737 | BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06767956 | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07030699 | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma(ECLAT) | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | withdrawn | Phase 2 | 0 | Eric Jacobsen, MDOTHER | 0 | Apr 1, 2026 | clinicaltrials |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation(Mandolin) | withdrawn | Phase 2 | 0 | Epizyme, Inc.INDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06670105 | A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)(B-ALL) | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma(BIOSELECT) | withdrawn | Phase 1 / Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | withdrawn | Phase 2 | 0 | Inhye AhnOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05486481 | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | withdrawn | Phase 1 / Phase 2 | 0 | Alfred Chung, MDOTHER | 0 | Mar 6, 2025 | clinicaltrials |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | withdrawn | Phase 2 | 0 | Jack Khouri, MDOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04148742 | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) | withdrawn | Phase 1 / Phase 2 | 0 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | GlyPharma TherapeuticsINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT05050305 | Marizomib Central Nervous System (CNS) | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 10, 2024 | clinicaltrials |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART A) | withdrawn | Phase 1 / Phase 2 | 0 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | withdrawn | Phase 2 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | withdrawn | Phase 2 | 0 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | withdrawn | Phase 1 / Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | withdrawn | Phase 1 / Phase 2 | 0 | LaNova Medicines LimitedINDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.(PENTI-MIDAS) | withdrawn | Phase 2 | 0 | Nantes University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials